Clinical trials: Hematological Neoplasm
Bone Marrow Transplant Complications, Graft-versus-Host Disease
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for…
- Trial name
- HORIZONS (NCT06910969)
- Testing
- HORIZONS Intervention, Minimally enhanced usual care
- Where
- 2 sites in United States
- Volunteers
- 350 people
- Sponsor
- Massachusetts General Hospital
Haematologic Neoplasms
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in…
- Trial name
- NCT07064122
- Testing
- AZD2962
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Blood Cancer
Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy
The purpose of this study is to determine which of two approaches is helpful to support caregivers of patients undergoing Hematopoietic Stem Cell Transplant (HSCT) or Chimeric Antigen Receptors (CAR) T-cell therapy at Seidman…
- Trial name
- NCT04390542
- Testing
- Psychoeducation
- Sponsor
- Case Comprehensive Cancer Center
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Myelofibrosis
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
The study is a designed to evaluate safety and activity of APG-1252 when administered as monotherapy and in combination with ruxolitinib in previously ruxolitinib treated myelofibrosis patients.
- Trial name
- NCT04354727
- Testing
- APG-1252, Ruxolitinib
- Where
- 2 sites in United States
- Sponsor
- Ascentage Pharma Group Inc.
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Hematological Malignancy, Leukemia
Halt Aging in Survivors of Blood Cancers
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions.
- Conditions
- Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma
- Trial name
- HALTAging-1 (NCT07292272)
- Testing
- Behavioral Coaching Intervention, Virtual Exercise Platform
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Nebraska
Hematologic Neoplasms
Immunological Profile for Patients Treated With CAR-T Cells
In the frame of Si-CART study, blood will be collected from patients treated with CAR-T cells: before (at Day (D)-6 and D0 before cells injection), post infusion at D3, D5,D7, D9, D11, D14, D18, D 21, Month (M) 2 and M12 post…
- Trial name
- SI-CART (NCT05054231)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Institut Paoli-Calmettes
Hematological Neoplasms, Hematopoietic Stem Cell Transplantation
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
- Trial name
- NCT00582894
- Testing
- Busulfex, Fludarabine, ALemtuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Oklahoma
Hematologic Malignancy
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
- Trial name
- NCT07511127
- Testing
- Maribavir
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Ruijin Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Myelofibrosis (MF), Polycythemia Vera
MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation…
- Conditions
- Myelofibrosis (MF), Polycythemia Vera, Essential Thrombocythaemia
- Trial name
- NCT07863466
- Where
- Italy
- Volunteers
- 1,190 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hematological Cancer
MethylphenIdate for Fatigue in Haematological Cancer
Cancer related fatigue (CRF) is the most debilitating problem for patients with haematological cancer. CRF severely reduces quality of life (QoL), functional capacity, impacts health behavior, recovery and furthermore no approved…
- Trial name
- MICRO (NCT03218254)
- Testing
- Methylphenidate
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Henrik Frederiksen
PTLD, Lymphoid Tumor
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
This is an open label, risk-stratified, sequential treatment, phase 2 study of newly diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30 expression.
- Conditions
- PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD
- Trial name
- NCT04138875
- Testing
- Rituximab, Brentuximab Vedotin, Bendamustine
- Where
- 2 sites in United States
- Sponsor
- Yale University
Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The primary aim of this trial is to determine the effect of a short course (i.e., 3 cycles) of low-dose Bortezomib (Velcade) on bone remodeling and on disease progression.
- Trial name
- NCT01062230
- Testing
- Bortezomib (Velcade)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Hematologic Malignancies
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
Allogeneic stem cell transplantation is a potentially curative treatment for patients with many hematologic malignancies (e.g. leukemia, lymphoma, and myeloma with high risk of relapse). This process requires a suitable donor.
- Trial name
- NCT01749293
- Testing
- Haploidentical Transplant, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Illinois Chicago
Non-hodgkin's Lymphoma
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Phase I main objectives: To observe the safety and preliminary efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies, to determine the DLT and MTD, or MAD, and to…
- Trial name
- NCT06066203
- Testing
- GNC-035
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies
Randomized unblinded interventional clinical trial: Arm Intervention Experimental arm (n=150): Intervention group Administration of the MyPal ePRO system the intervention group will use the ePRO tools provided in the project.
- Trial name
- NCT04370457
- Testing
- Administration of the MyPal ePRO system
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Centre for Research and Technology Hellas
T-LGL Leukemia, NK-LGL Leukemia
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China.
- Trial name
- NICHE-LGLL (NCT07019766)
- Testing
- A combined retrospective and prospective observational follow-up
- Where
- China
- Volunteers
- 9,999 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for…
- Conditions
- Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT05088356
- Testing
- Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.